EGFR and glioblastoma: Taking advantage of the fact that EGFR amplification is very common in GBM [115,116], several studies have assessed the use of targeting agents against EGFR including monoclonal antibodies, small molecule tyrosine kinase inhibitors, and vaccines [115].